Table 1 Patient characteristics
| Ā | Non-PAD (nā=ā106) | PAD (nā=ā22) | p | ||||
|---|---|---|---|---|---|---|---|
Age (year) | 59.8 | (50.0, 70.0) | 71.8 | (64.0,81.0) | 0.0004 | ||
Dialysis Vintage (years) | 7.0 | (3.0, 14.0) | 9.0 | (7.0, 11.0) | NS | ||
BMI (kg/m2) | 23.2 | Ā± | 4.4 | 22.1 | Ā± | 4.5 | NS |
| Ā | Yes | No | Ā | Yes | No | Ā | Ā |
DM (y/n %) | 30 | 76 | 28.30% | 13 | 9 | 59.10% | 0.0115 |
Sex (male/female) | 19 | 87 | 82.10% | 4 | 18 | 81.80% | NS |
SBP (mmHg) | 149.3 | Ā± | 21.3 | 146.2 | Ā± | 21.9 | NS |
DBP (mmHg) | 81 | Ā± | 13.7 | 71.3 | Ā± | 13.5 | 0.0056 |
Online HDF (y/n) | 16 | 106 | 15.10% | 3 | 22 | 13.60% | NS |
Total Fluid Removal (kg) | 3.3 | 2.7 | 3.8 | 2.6 | 2.2 | 3.4 | 0.0134 |
KtV | 1.4 | (1.4, 1.5) | 1.4 | 1.3 | 1.5 | 0.893 | |
CGR (%) | 104.8 | (100.0, 109.6) | 86.3 | (78.3, 94.3) | 0.0002 | ||
nPCR (g/kg/day) | 0.9 | (0.9, 1.0) | 0.8 | (0.8, 0.9) | 0.006 | ||
Anticoagulant for dialysis n (%) | Hepaline | Low Molecular | Nafamostat | Hepaline | Low Molecular | Nafamostat | Ā |
| Ā | 77 / 72.6% | 22 / 20.8% | 6 / 5.7% | 11 / 50.0% | 7 / 31.8% | 6 / 5.7% | Ā |
Fontaine grade I n (%) | 99 | Ā | 93.40% | 8 | Ā | 36.40% | Ā |
Fontaine grade II n (%) | 7 | Ā | 6.60% | 3 | Ā | 13.60% | Ā |
Fontaine grade III n (%) | 0 | Ā | 0% | 5 | Ā | 22.70% | Ā |
Fontaine grade IV n (%) | 0 | Ā | 0% | 6 | Ā | 27.30% | Ā |
Hb (g/dL) | 11.2 | Ā± | 0.9 | 10.8 | Ā± | 1.2 | NS |
Ht (%) | 34.5 | Ā± | 2.8 | 34 | Ā± | 4.0 | NS |
Fe (Ī¼g/dL) | 76.1 | Ā± | 22.5 | 61.7 | Ā± | 22.2 | 0.0114 |
Ferritin (ng/mL) | 41.5 | (20.3, 81.7) | 60.3 | (28, 106.3) | NS | ||
TSAT (%) | 26.8 | (21.7, 33.9) | 24.3 | (16.5, 29.8) | NS | ||
BUN (mg/dL) | 68.2 | (65.5, 70.9) | 58.6 | (51.8, 65.4) | 0.0111 | ||
Cr (g/dL) | 12.5 | (11.9, 13.0) | 9.5 | (8.5, 10.5) | <ā0.0001 | ||
UA (mg/dL) | 7.6 | (6.6, 8.5) | 7.2 | (5.6, 7.9) | 0.0326 | ||
CRP (ng/mL) | 0.2 | (0.1, 0.4) | 0.5 | (0.1, 1.2) | 0.0104 | ||
Na (mEq/L) | 139.2 | (137.3, 140.5) | 137.5 | (136.2, 139.2) | NS | ||
K (mEq/L) | 4.9 | (4.5, 5.2) | 4.4 | (4.2, 4.8) | 0.004 | ||
Cl (mEq/L) | 101.7 | (100,0103.3) | 101.7 | (100, 104.0) | NS | ||
Pi (mg/dL) | 5.6 | (5.4, 5.9) | 5.1 | (4.6, 5.7) | 0.1148 | ||
Ca (mg/dL) | 8.5 | (8.1, 9.2) | 8.2 | (7.9, 8.6) | NS | ||
iPTH (pg/mL) | 254.5 | (224.4, 284.7) | 264.9 | (194.2, 335.6) | 0.7828 | ||
Alb (g/mL) | 3.7 | (3.6, 3.7) | 3.3 | (3.1, 3.5) | 0.0003 | ||
Ret (%0) | 16.1 | (15, 17.1) | 16.8 | (13.5, 20.1) | 0.6495 | ||
TP (g/dL) | 7.0 | (6.7, 7.2) | 6.9 | (6.7, 7.3) | NS | ||
Tcho (mg/dL) | 164.9 | (158.7, 171.2) | 137.8 | (127.1, 148.4) | <ā0.0001 | ||
TG (mg/dL) | 143.1 | (125.0, 161.3) | 94.7 | (74.3, 115.2) | 0.0006 | ||
LDL (mg/dL) | 88.0 | (74.0, 114.5) | 68.3 | (58.8, 82.3) | 0.003 | ||
HDL (mg/dL) | 47.9 | (45.1, 50.7) | 45.8 | (39.7, 51.9) | 0.5126 | ||
Ī²2MG (mg/L) | 28.1 | (26.9, 29.2) | 31.1 | (28.1, 34.1) | 0.061 | ||
ESA dose (Ī¼g/week) | 6.6 | (3.0, 10.0) | 11.3 | (4.2, 17.8) | NS | ||
Vitamin D (Ī¼g/week) | 0.0 | (0.0, 2.5) | 0.0 | (0.0, 2.5) | NS | ||
Cinacalcet (mg/week) | 0.0 | (0.0350.0) | 87.5 | (0.0350.0) | NS | ||
| Ā | Yes | No | Yes (%) | Yes | No | Yes (%) | Ā |
Ca antagonist (y/n) | 62 | 44 | 58.50% | 5 | 17 | 22.70% | 0.0041 |
ACE/ARB (y/n) | 30 | 76 | 28.30% | 5 | 17 | 22.70% | NS |
Alpha blocker (y/n) | 5 | 101 | 4.70% | 2 | 20 | 9.10% | NS |
Alpha beta blocker (y/n)ā+āB35 | 35 | 71 | 30.00% | 6 | 16 | 27.30% | NS |
Aspirin (y/n) | 21 | 85 | 19.80% | 9 | 13 | 40.90% | 0.0506 |
Ticlopidine hydrochloride (y/n) | 3 | 103 | 2.80% | 0 | 22 | 0.00% | NS |
Clopidogrel sulfate (y/n) | 8 | 98 | 7.60% | 4 | 18 | 18.20% | NS |
Cilostazol (y/n) | 1 | 105 | 0.90% | 3 | 19 | 13.60% | 0.016 |